Multiple evidence syntheses are refining how targeted cancer drugs perform across molecular subtypes and resistance contexts. A systematic review and meta-analysis in advanced gastrointestinal stromal tumors found efficacy for avapritinib versus sunitinib diverges by genotype. In pooled analyses, avapritinib showed higher objective response rates but shorter progression-free survival in PDGFRA D842V-mutant disease, while sunitinib provided longer disease control in KIT-mutant, imatinib-refractory settings. Another mechanistic report in castration-resistant prostate cancer identified a TRIM25–KLF5–SLC7A11 axis that degrades KLF5 and promotes enzalutamide resistance by suppressing ferroptosis. A longitudinal plasma proteomics study in small cell lung cancer further described distinct resistance and survival signatures, including a baseline prognostic five-protein panel. Together, the updates underscore that response and durability are being mapped increasingly to genotype, pathway state, and measurable proteomic programs.